Business Description
Tectonic Therapeutic Inc
NAICS : 541713
SIC : 2834
ISIN : US8789721086
Total Employee Number:
60Description
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 51.62 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.8 | |||||
3-Year EPS without NRI Growth Rate | -22 | |||||
3-Year FCF Growth Rate | -17.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.99 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.45 | |||||
9-Day RSI | 59.63 | |||||
14-Day RSI | 58.76 | |||||
3-1 Month Momentum % | 4.29 | |||||
6-1 Month Momentum % | 42.25 | |||||
12-1 Month Momentum % | 16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.29 | |||||
Quick Ratio | 22.29 | |||||
Cash Ratio | 21.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -1.86 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -34.13 | |||||
ROA % | -32.57 | |||||
ROIC % | -1043.89 | |||||
3-Year ROIIC % | 975.17 | |||||
ROC (Joel Greenblatt) % | -2226 | |||||
ROCE % | -33.81 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.22 | |||||
Price-to-Tangible-Book | 3.22 | |||||
EV-to-EBIT | -5.97 | |||||
EV-to-EBITDA | -6.06 | |||||
EV-to-FCF | -7.04 | |||||
| Price-to-Net-Current-Asset-Value | 3.34 | |||||
| Price-to-Net-Cash | 3.41 | |||||
Earnings Yield (Greenblatt) % | -16.75 | |||||
FCF Yield % | -9.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TECX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tectonic Therapeutic Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.57 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 66.98 | ||
| 14-Day RSI | 58.76 | ||
| 14-Day ATR ($) | 2.182817 | ||
| 20-Day SMA ($) | 32.52425 | ||
| 12-1 Month Momentum % | 16 | ||
| 52-Week Range ($) | 14.385 - 39.5278 | ||
| Shares Outstanding (Mil) | 19.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tectonic Therapeutic Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tectonic Therapeutic Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 73 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 29.56 (+0.24%) | ||
| General meeting for 2026 | 2026-06-08 09:00 | 29.00 (-0.45%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 29.02 (-1.02%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 13:40 | 33.24 (-1.86%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 11:10 | 24.40 (+10.58%) | ||
| Annual report for 2025 | 2026-02-26 | 23.11 (+8.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 23.11 (+8.29%) | ||
| Evercore 8(th) Annual Healthcare Conference | 2025-12-03 | 19.02 (-6.81%) | ||
| Piper Sandler 37(th) Annual Healthcare Conference | 2025-12-02 15:30 | 20.47 (-3.72%) |
Show
Entries
Tectonic Therapeutic Inc Frequently Asked Questions
What is Tectonic Therapeutic Inc(TECX)'s stock price today?
The current price of TECX is $37.46. The 52 week high of TECX is $39.53 and 52 week low is $14.39.
When is next earnings date of Tectonic Therapeutic Inc(TECX)?
The next earnings date of Tectonic Therapeutic Inc(TECX) is 2026-11-06 Est..
Does Tectonic Therapeutic Inc(TECX) pay dividends? If so, how much?
Tectonic Therapeutic Inc(TECX) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million | 2024-06-20 |
Articles on Tectonic Therapeutic Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers